Inhibition of cyclooxygenase-2 causes regression of gastric adenomas in trefoil factor 1 deficient mice

International Journal of Cancer

Volumn 131, Issue 5, 2012, Pages 1032-1041

  Thiel, Alexandra ^a,b   Narko, Kirsi ^a,b   Heinonen, Mira ^a,b   Hemmes, Annabrita ^a,b   Tomasetto, Catherine ^c   Rio, Marie Christine ^c   Haglund, Caj ^a   Mäkel̈a, Tomi P ^b,d   Ristimäki, Ari ^a,b  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^b UNIVERSITY OF HELSINKI   (Finland)

^c UNIVERSITÉ DE STRASBOURG   (France)

^d UNIVERSITY OF HELSINKI   (Finland)

Author keywords

Adenoma; Carcinogenesis; Celecoxib; Cyclooxygenase 2; Prostaglandin endoperoxide synthase 2; Trefoil factor 1

Indexed keywords

CELECOXIB; CYCLOOXYGENASE 2; MESSENGER RNA; TREFOIL FACTOR 1 PROTEIN; TREFOIL PEPTIDE; UNCLASSIFIED DRUG;

ADENOMA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARCINOGENESIS; CHRONIC INFLAMMATION; CONTROLLED STUDY; CYCLOOXYGENASE 2 GENE; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME INHIBITION; EPITHELIAL MESENCHYMAL TRANSITION; GENE DELETION; GENE FUNCTION; GENE IDENTIFICATION; GENE LOCATION; HISTOPATHOLOGY; IN VIVO STUDY; LYMPHOCYTIC INFILTRATION; MALE; MOUSE; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; STOMACH TUMOR; STOMACH ULCER; TUMOR REGRESSION; TUMOR VOLUME;

ADENOMA; ANIMALS; APOPTOSIS; BLOTTING, WESTERN; CELL PROLIFERATION; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; IMMUNOENZYME TECHNIQUES; MALE; MICE; MICE, KNOCKOUT; PEPTIDES; PYRAZOLES; STOMACH; STOMACH NEOPLASMS; SULFONAMIDES;

EID: 84863215731     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.27331     Document Type: Article

References (48)

1. Simmons DL, Botting RM, Hla T. Cyclooxygenase isozymes: the biology of prostaglandin synthesis and inhibition. Pharmacol Rev 2004;56:387-437. (Pubitemid 39096597)
2. Saukkonen K, Rintahaka J, Sivula A, Buskens CJ, Van Rees BP, Rio MC, Haglund C, Van Lanschot JJ, Offerhaus GJ, Ristimäki A. Cyclooxygenase-2 and gastric carcinogenesis. APMIS 2003;111:915-25. (Pubitemid 37352608)
3. Greenhough A, Smartt HJ, Moore AE, Roberts HR, Williams AC, Paraskeva C, Kaidi A. The COX-2/PGE2 pathway: key roles in the hallmarks of cancer and adaptation to the tumour microenvironment. Carcinogenesis 2009;30:377-86.
4. Menter DG, Schilsky RL, DuBois RN. Cyclooxygenase-2 and cancer treatment: understanding the risk should be worth the reward. Clin Cancer Res 2010;16:1384-90.
5. Ristimäki A, Honkanen N, Jänkälä H, Sipponen P, Härkönen M. Expression of cyclooxygenase-2 in human gastric carcinoma. Cancer Res 1997;57:1276-80. (Pubitemid 27152551)
6. Saukkonen K, Nieminen O, van Rees B, Vilkki S, Härkönen M, Juhola M, Mecklin JP, Sipponen P, Ristimäki A. Expression of cyclooxygenase-2 in dysplasia of the stomach and in intestinal-type gastric adenocarcinoma. Clin Cancer Res 2001;7:1923-31. (Pubitemid 32994826)
7. Mrena J, Wiksten JP, Thiel A, Kokkola A, Pohjola L, Lundin J, Nordling S, Ristimäki A, Haglund C. Cyclooxygenase-2 is an independent prognostic factor in gastric cancer and its expression is regulated by the messenger RNA stability factor HuR. Clin Cancer Res 2005;11:7362-8. (Pubitemid 41507695)
8. Park ES, Do IG, Park CK, Kang WK, Noh JH, Sohn TS, Kim S, Kim MJ, Kim KM. Cyclooxygenase-2 is and idependent prognostic factor in gastric carcinoma patients receiving adjuvant chemotherapy and is not associated with EBV infection. Clin Cancer Res 2009;15:291-8.
9. Oshima H, Oshima M, Inaba K, Taketo MM. Hyperplastic gastric tumors induced by activated macrophages in COX-2/mPGES-1 transgenic mice. EMBO J 2004;23:1669-78. (Pubitemid 38579527)
10. Udd L, Katajisto P, Rossi DJ, Lepisto A, Lahesmaa AM, Ylikorkala A, Jarvinen HJ, Ristimaki AP, Makela TP. Suppression of peutzjeghers polyposis by inhibition of cyclooxygenase-2. Gastroenterology 2004;127:1030-7. (Pubitemid 39345871)
11. Kanda N, Seno H, Kawada M, Sawabu T, Uenoyoma Y, Nakajima T, Konda Y, Fukui H, Takeuchi T, Chiba T. Involvement of cyclooxygenase-2 in gastric mucosal hypertrophy in gastrin transgenic mice. Am J Physiol Gastrointest Liver Physiol 2006;290:G519-27.
12. Oshima H, Matsunaga A, Fujimura T, Tsukamoto T, Taketo MM, Oshima M. Carcinogenesis in mouse stomach by simultaneous activation of the Wnt signaling and prostaglandin E2 pathway. Gastroenterology 2006;131:1086-95. (Pubitemid 44498691)
13. Lefebvre O, Chenard MP, Masson R, Linares J, Dierich A, LeMeur M, Wendling C, Tomasetto C, Chambon P, Rio MC. Gastric mucosa abnormalities and tumorigenesis in mice lacking the pS2 trefoil protein. Science 1996;274:259-62. (Pubitemid 26353205)
14. Taupin D, Podolsky DK. Trefoil factors: initiators of mucosal healing. Nat Rev Mol Cell Biol 2003;4:721-32. (Pubitemid 37082187)
15. Tomasetto C, Rio MC. Pleiotropic effects of trefoil factor 1 deficiency. Cell Mol Life Sci 2005;62:2916-20. (Pubitemid 43004744)
16. Machado JC, Carneiro F, Ribeiro P, Blin N, Sobrinho-Simoes M. pS2 protein expression in gastric carcinoma. an immunohistochemical and immunoradiometric study. Eur J Cancer 1996;32A:1585-90. (Pubitemid 26279128)
17. Milne AN, Carvalho R, Morsink FM, Musler AR, de Leng WW, Ristimaki A, Offerhaus GJ. Earlyonset gastric cancers have a different molecular expression profile than conventional gastric cancers. Mod Pathol 2006;19:564-72.
18. Saukkonen K, Tomasetto C, Narko K, Rio MC, Ristimäki A. Cyclooxygenase-2 expression and effect of celecoxib in gastric adenomas of trefoil factor 1-deficient mice. Cancer Res 2003;63:3032-6. (Pubitemid 36735846)
19. Dinchuk JE, Car BD, Focht RJ, Johnston JJ, Jaffee BD, Covington MB, Contel NR, Eng VM, Collins RJ, Czerniak PM. Renal abnormalities and an altered inflammatory response in mice lacking cyclooxygenase II. Nature 1995;378:406-9.
20. Yu Y, Fan J, Chen XS, Wang D, Klein-Szanto AJ, Campbell RL, FitzGerald GA, Funk CD. Genetic model of selective COX2 inhibition reveals novel heterodimer signaling. Nat Med 2006;12:699-704. (Pubitemid 43865241)
21. Oshima H, Itadani H, Kotani H, Taketo MM, Oshima M. Induction of prostaglandin E2 pathway promotes gastric hamartoma development with suppression of bone morphogenetic protein signaling. Cancer Res 2009;69:2729-33.
22. Jacoby RF, Seibert K, Cole CE, Kelloff G, Lubet RA. The cyclooxygenase-2 inhibitor celecoxib is a potent preventive and therapeutic agent in the min mouse model of adenomatous polyposis. Cancer Res 2000;60:5040-4.
23. Reddy BS, Hirose Y, Lubet R, Steele V, Kelloff G, Paulson S, Seibert K, Rao CV. Chemoprevention of colon cancer by specific cyclooxygenase-2 inhibitor, celecoxib, administered during different stages of carcinogenesis. Cancer Res 2000;60:293-7. (Pubitemid 30070754)
24. Qian BZ, Pollard JW. Macrophage diversity enhances tumor progression and metastasis. Cell 2010;141:39-51.
25. Oshima H, Hioki K, Popivanova BK, Oguma K, Van Rooijen N, Ishikawa TO, Oshima M. Prostaglandin E 2 signaling and bacterial infection recruit tumor-promoting macrophages to mouse gastric tumors. Gastroenterology 2011;140:596, 607.e7.
26. Allavena P, Sica A, Garlanda C, Mantovani A. The yin-yang of tumor-associated macrophages in neoplastic progression and immune surveillance. Immunol Rev 2008;222:155-61. (Pubitemid 351430369)
27. Fu SL, Wu YL, Zhang YP, Qiao MM, Chen Y. Anti-cancer effects of COX-2 inhibitors and their correlation with angiogenesis and invasion in gastric cancer. World J Gastroenterol 2004;10:1971-4. (Pubitemid 39029305)
28. Iwata C, Kano MR, Komuro A, Oka M, Kiyono K, Johansson E, Morishita Y, Yashiro M, Hirakawa K, Kaminishi M, Miyazono K. Inhibition of cyclooxygenase-2 suppresses lymph node metastasis via reduction of lymphangiogenesis. Cancer Res 2007;67:10181-9. (Pubitemid 350070790)
29. Mizuno H, Sakamoto C, Matsuda K, Wada K, Uchida T, Noguchi H, Akamatsu T, Kasuga M. Induction of cyclooxygenase 2 in gastric mucosal lesions and its inhibition by the specific antagonist delays healing in mice. Gastroenterology 1997;112:387-97. (Pubitemid 27078825)
30. Watanabe T, Higuchi K, Taira K, Sasaki E, Shiba M, Tominaga K, Fujiwara Y, Oshitani N, Arakawa T. Rebamipide reduces delay in gastric ulcer healing in cyclooxygenase-2-deficient mice. Dig Dis Sci 2005;50(Suppl 1):S63-9. (Pubitemid 41380800)
31. Laine L, Takeuchi K, Tarnawski A. Gastric mucosal defense and cytoprotection: bench to bedside. Gastroenterology 2008;135:41-60. (Pubitemid 351899027)
32. Filaretova L, Tanaka A, Komoike Y, Takeuchi K. Selective cyclooxygenase-2 inhibitor induces gastric mucosal damage in adrenalectomized rats. Inflammopharmacology 2002;10:413-22. (Pubitemid 36637460)
33. Kato S, Ogawa Y, Kanatsu K, Okayama M, Watanabe T, Arakawa T, Takeuchi K. Ulcerogenic influence of selective cyclooxygenase-2 inhibitors in the rat stomach with adjuvant-induced arthritis. J Pharmacol Exp Ther 2002;303:503-9. (Pubitemid 35231219)
34. Farrell JJ, Taupin D, Koh TJ, Chen D, Zhao CM, Podolsky DK, Wang TC. TFF2/SP-deficient mice show decreased gastric proliferation, increased acid secretion, and increased susceptibility to NSAID injury. J Clin Invest 2002;109:193-204. (Pubitemid 34083739)
35. Carothers AM, Moran AE, Cho NL, Redston M, Bertagnolli MM. Changes in antitumor response in C57BL/6J-min/+ mice during long-term administration of a selective cyclooxygenase-2 inhibitor. Cancer Res 2006;66:6432-8.
36. van Rees BP, Saukkonen K, Ristimaki A, Polkowski W, Tytgat GN, Drillenburg P, Offerhaus GJ. Cyclooxygenase-2 expression during carcinogenesis in the human stomach. J Pathol 2002;196:171-9. (Pubitemid 34110898)
37. Shattuck-Brandt RL, Varilek GW, Radhika A, Yang F, Washington MK, DuBois RN. Cyclooxygenase 2 expression is increased in the stroma of colon carcinomas from IL-10(-/-) mice. Gastroenterology 2000;118:337-45. (Pubitemid 30067507)
38. Hull MA, Booth JK, Tisbury A, Scott N, Bonifer C, Markham AF, Coletta PL. Cyclooxygenase 2 is upregulated and localized to macrophages in the intestine of min mice. Br J Cancer 1999;79:1399-405. (Pubitemid 29116796)
39. Sonoshita M, Takaku K, Oshima M, Sugihara K, Taketo MM. Cyclooxygenase-2 expression in fibroblasts and endothelial cells of intestinal polyps. Cancer Res 2002;62:6846-9. (Pubitemid 35424071)
40. Yashiro M, Nakazawa K, Tendo M, Kosaka K, Shinto O, Hirakawa K. Selective cyclooxygenase-2 inhibitor downregulates the paracrine epithelial-mesenchymal interactions of growth in scirrhous gastric carcinoma. Int J Cancer 2007;120:686-93. (Pubitemid 44969042)
41. Tomita H, Takaishi S, Menheniott TR, Yang X, Shibata W, Jin G, Betz KS, Kawakami K, Minamoto T, Tomasetto C, Rio MC, Lerkowit N, et al. Inhibition of gastric carcinogenesis by the hormone gastrin is mediated by suppression of TFF1 epigenetic silencing. Gastroenterology 2011;140:879-91.
42. Bresalier RS, Sandler RS, Quan H, Bolognese JA, Oxenius B, Horgan K, Lines C, Riddell R, Morton D, Lanas A, Konstam MA, Baron JA, et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005;352:1092-102. (Pubitemid 40365350)
43. Solomon SD, McMurray JJ, Pfeffer MA, Wittes J, Fowler R, Finn P, Anderson WF, Zauber A, Hawk E, Bertagnolli M, Adenoma prevention with celecoxib (APC) Study Investigators. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 2005;352:1071-80. (Pubitemid 40365348)
44. Nussmeier NA, Whelton AA, Brown MT, Langford RM, Hoeft A, Parlow JL, Boyce SW, Verburg KM. Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. N Engl J Med 2005;352:1081-91. (Pubitemid 40365349)
45. Marnett LJ. The COXIB experience: a look in the rearview mirror. Annu Rev Pharmacol Toxicol 2009;49:265-90.
46. Feng GS, Ma JL, Wong BC, Zhang L, Liu WD, Pan KF, Shen L, Zhang XD, Li J, Xia HH, Li JY, Lam SK, et al. Celecoxib-related gastroduodenal ulcer and cardiovascular events in a randomized trial for gastric cancer prevention. World J Gastroenterol 2008;14:4535-9.
47. Tendo M, Yashiro M, Nakazawa K, Yamada N, Sawada T, Ohira M, Hirakawa K. A synergic inhibitory-effect of combination with selective cyclooxygenase-2 inhibitor and S-1 on the peritoneal metastasis for scirrhous gastric cancer cells. Cancer Lett 2006;244:247-51. (Pubitemid 44485881)
48. Bertagnolli MM, Eagle CJ, Zauber AG, Redston M, Breazna A, Kim K, Tang J, Rosenstein RB, Umar A, Bagheri D, Collins NT, Burn J, et al. Five-year efficacy and safety analysis of the adenoma prevention with celecoxib trial. Cancer Prev Res 2009;2:310-21.